Angiotensin II (Ang II), when administered to either tubular lumen or peritubular capillary, exerts a biphasic action on proximal fluid uptake rate. At low concentrations, (10 -12 -10 -10 M) Ang II stimulates fluid transport, whereas higher doses (>10 -9 M) inhibit. Ang II is secreted into the lumen in the proximal tubule and the concentration of Ang II in the proximal lumen has been reported to be in the nanomolar range, 100-1,000 times higher than in peritubular blood. We investigated the regulation of renal proximal fluid transport by luminal (predominantly locally produced) and peritubular capillary (circulatory) Ang II in anaesthetised rats, using a selective AT 1 -receptor antagonist, candesartan.
Introduction
Angiotensin II (Ang II), when added to either the tubule lumen or peritubular capillary, exerts a dose-dependent biphasic action on proximal fluid reabsorption. Experiments conducted in vivo. [1] [2] [3] [4] and in vitro [5] [6] [7] showed that low concentrations of Ang II (10 -12 -10 -10 M) stimulate fluid transport while higher concentrations (>10 -9 M) cause inhibition. The concentration of Ang II in the proximal tubular fluid is reported to be in the nanomolar range, 100-1,000 times higher than in peritubular blood 8, 9 and it has been inferred that the proximal tubule secretes Ang II into the tubular lumen. It is likely that luminal Ang II stimulates fluid uptake via apical angiotensin AT 1 -receptors. 10 Experiments in the isolated perfused proximal tubule showed that luminal addition of Ang II caused a similar, but more potent, biphasic effect when compared with peritubular Ang II. 11 Under most conditions, there will be Ang II in both luminal and peritubular fluids, but the relative contributions and functional significance of the actions of this peptide on fluid transport are unclear and, due to the biphasic nature of the concentration-dependent responses, these effects are difficult to predict.
We investigated the regulation of renal proximal fluid transport by luminal (predominantly locally-produced) and peritubular capillary (circulatory) Ang II, using a selective angiotensin receptor blocker (ARB), candesartan, in anaesthetised rats. Digital image capture and analysis of shrinking split drop microperfusion was used to assess the rate of fluid uptake.
Materials and methods
Male Wistar rats (body weight 185-440 g) were anaesthetised with intraperitoneal (i.p.) inactin (110 mg/kg body weight [BW]) and placed on a thermostatically-controlled heated table to maintain body temperature at 37°C. A tracheostomy was performed and the right carotid artery cannulated for blood sampling and for arterial blood pressure recording (Grass polygraph model 7DAG, USA) throughout the experiment. The right jugular vein was cannulated and infused with 0.9% NaCl at the rate of 1.6 ml/hr/100 g BW. The left kidney was prepared for micropuncture as previously reported. 12 After a 1-hour equilibration period, shrinking split-drop microperfusion was performed in midproximal convoluted tubule segments visible on the kidney surface. Sudan Blackstained castor oil was infused into the proximal tubule from one barrel of a double-barrelled micropipette. Artificial tubular fluid (ATF; in mM: NaCl 145, NaHCO 3 . Animals were randomly allocated to four groups according to the schedule shown in Figure 1 .
A second series of experiments was performed using two groups of animals as shown in Figure 2 . Mean fluid uptake rate was determined in 3-5 tubules receiving artificial tubular fluid (ATF) and then in another two groups of 3-5 tubules following the addition of 10 -9 M Ang II to the luminal fluid and with luminal addition of 10 -9 M Ang II combined with simultaneously capillary perfusion with either peritubular fluid (PTF) or PTF containing 10 -8 M candesartan.
Statistics
For each animal, a mean value for fluid uptake rate was determined from each set of 3-5 tubules during each treatment period. The mean values for each period in each animal were then used to determine the mean values for that period for the group of animals. All values are expressed as means ± SEM. A paired t-test was performed for each group and compared with the corresponding controls. An unpaired t-test and ANOVA was used to compare the mean values between groups in each series of experiments.
Results
The first series of experiments ( Figure 1 ) was designed to determine the effects on proximal fluid absorption rate of luminal perfusion with artificial tubular fluid with and without the ARB, candesartan, together with simultaneous capillary perfusion with or without candesartan. Experiments were performed in four groups of rats (ATF/PTF, ATF+candesartan/PTF, ATF/PTF+ candesartan and ATF+candesartan/PTF+candesartan).The effects of luminal addition of Ang II and of capillary perfusion with candesartan were studied in the second series ( Figure 2 ).The mean initial values for fluid uptake rate in these two series of experiments (Jv a , x 10 -4 mm 3 /mm 2 /s) were between 2.81 ± 0.22 and 3.51 ± 0.16. These values were not significantly different.
As shown in Figure 1 , peritubular capillary perfusion with PTF (ATF/PTF) reduced mean fluid uptake rate by 27% (initial 2.94 ± 0.17, ATF/PTF 2.10 ± 0.12 x 10 -4 mm 3 /mm 2 /s; n=15, p<0.05). Luminal addition of candesartan (10 -8 M) alone resulted in 19% and 25% reduction in fluid uptake compared with initial values (initial 3.02 ± 0.19, ATF+10 -8 M candesartan 2.42 ± 0.11 x 10 -4 mm 3 /mm 2 /s; n=8, p<0.05) and (initial 3.51 ± 0.16, ATF+10 -8 M candesartan 2.94 ± 0.17 x 10 -4 mm 3 /mm 2 /s; n=6, p<0.05), respectively.
When peritubular capillaries were perfused with PTF alone or PTF with candesartan, the fluid uptake rates decreased by 28% and 43% compared with the corresponding initial values (initial 3.02 ± 0.19, ATF+candesartan/PTF 2.14 ± 0.11 In the second series of experiments, the effects of luminal addition of Ang II in the presence and absence of candesartan in the peritubular capillary were examined. As shown in Figure 2 ,Ang II (10 -9 M) administered into tubular fluid increased Jv a by 22% (initial 2.83 ± 0.11, ATF+Ang II 3.44 ± 0.17 x 10 -4 mm 3 /mm 2 /s; n=7, p<0.05). However, when the peritubular capillaries were simultaneously perfused with PTF alone, the mean Jv a decreased by 19% from its initial value and by 32% from the Ang II-stimulated fluid uptake value (initial 2.83 ± 0.11, ATF+Ang II 3.44 ± 0.17, and ATF+Ang II/PTF 2.28 ± 0.14 x 10 -4 mm 3 /mm 2 /s; n=7, p<0.01).
As shown in Figure 2 , stimulation of fluid uptake rate by luminal Ang II (10 -9 M) was not observed in all animals and Jv a values for the initial and treatment periods for this group were not different (initial 2.81 ± 0.22,ATF+Ang II 2.76 ± 0.14 x 10 -4 mm 3 /mm 2 /s; n=7). This may due to the order in which agents were presented to the tubule. It is noted that, in the animals that received capillary perfusion with 10 -8 M candesartan before luminal addition of 10 -9 Ang II, the stimulatory effect of Ang II was not observed. However, luminal addition of 10 -9 Ang II, combined with simultaneous capillary perfusion of 10 -8 M candesartan, resulted in a 37% decrease in fluid uptake rate (initial 2.81 ± 0.22, ATF+Ang II/PTF+candesartan 1.72 ± 0.14 x 10 -4 mm 3 /mm 2 /s; n=7, p<0.05).
Discussion
This in vivo study indicates that both peritubular and luminal Ang II contribute to the regulation of proximal fluid absorption. A similar conclusion was reached following a previous in vitro study by Li et al. 11 In the present study, the specific ARB, candesartan, was used to suppress the activity of endogenous Ang II in either or both of the luminal and peritubular compartments adjacent to the tubular epithelium. Mean fluid uptake rates decreased by 19% and 25% when candesartan alone was added into the proximal lumen, supporting the stimulatory role of endogenous luminal Ang II on fluid uptake as previously reported. 10 The results reported here extend the work reported in previous in vivo studies, in which peritubular and luminal effects of ARBs have been investigated separately, though not together. 13 During the perfusion of peritubular capillaries with candesartan, mean fluid uptake rates decreased by between 33% and 43% compared with initial values. These changes most likely reflect blockade of the stimulatory action of Ang II present in the local peritubular circulation. When peritubular capillaries were perfused with an artificial plasma-like solution (ATF/PTF), mean fluid uptake decreased by 27%. This reduction may result from removal from the local peritubular capillaries of stimulatory factor(s), particularly peptide hormones such as Ang II. In support of this inference, it has been shown that, when exogenous Ang II was added to the capillary perfusion solution, the rate of proximal fluid absorption returned to initial values. 14 When candesartan was presented in either lumen (ATF+candesartan/PTF) or capillary fluids (ATF/PTF+candesartan), the extents of the observed reductions in fluid uptake rates (28% and 33%, respectively) were similar to the reduction (27%) observed when artificial peritubular fluid was used without candesartan (ATF/PTF). However, when candesartan was presented in both lumen and capillary simultaneously, the decrease in fluid uptake was significantly higher (43% in ATF+candesartan/PTF+candesartan compared with 28% in ATF+candesartan/PTF). It is concluded that, when Ang II is present in both luminal and peritubular fluids, the magnitude of the stimulatory action on proximal fluid transport is greater than when the peptide is present on only one side of the epithelium. In other words, expression of the maximum stimulatory action of Ang II requires that it be present in both luminal and peritubular fluids.
When Ang II (10 -9 M) was added to the lumen (ATF+Ang II/PTF, Figure 2 ), fluid uptake rate increased by 22%, as previously reported. 15 However, when the peritubular capillaries were then perfused with artificial fluid while the luminal fluid contained Ang II, mean fluid uptake rate decreased to a value that was 33% lower than the rate obtained during luminal treatment with Ang II, but not different from the initial, non-stimulated rate.These data indicate that the amount of Ang II added to in the luminal fluid (an initial concentration in the split-droplet of 10 -9 M), together with any additional Ang II secreted from the tubular cells, was not able to maintain the maximal fluid transport rate when peritubular Ang II was removed or minimised by perfusion of the capillaries.
In the last set of experiments, peritubular capillaries were perfused with 10 -8 M candesartan before luminal addition of 10 -9 M Ang II (ATF+Ang II/PTF+candesartan). When luminal Ang II was subsequently added, no stimulatory action of luminal Ang II was observed. However, when Ang II was presented in the lumen, fluid uptake rate decreased by 37% compared with either the initial value or the value observed during peritubular addition of candesartan. The extent of this reduction in the fluid uptake rate was significantly greater than that resulting from removal of circulating Ang II using PTF perfusion alone (ATF+Ang II/PTF). It is inferred that administration of candesartan to the capillaries can suppress the stimulatory action of Ang II more effectively than when added to the lumen. It is possible that continuous addition of candesartan by perfusion may result in movement of the antagonist from the peritubular side into the tubule, where it could exert its action on the luminal side. In conclusion, these data indicate that the presence of endogenous Ang II in both luminal fluid and peritubular blood is important for maximal expression of the stimulatory influence of this peptide on proximal fluid transport. This finding is significant, in that it implies that the relation between glomerular filtration rate and proximal reabsorption rate is influenced by the relative concentrations of Ang II in both luminal and peritubular fluid, representing predominantly filtered and secreted Ang II in the lumen and circulating Ang II in the capillaries. 
